Maja R. Radojčić
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Maja R. Radojčić has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Lingxiao Chen
Institute of Bone and Joint Research, The Kolling Institute, Faculty of Medicine and Health, University of Sydney, Sydney, Australia
2 shared publicationsNigel K Arden
Centre for Sport, Exercise and Osteoarthritis Research Versus Arthritis, University of Oxford, Oxford, United Kingdom; MRC Environmental Epidemiology Unit, University of Southampton, Southampton, United Kingdom
2 shared publications- Nigel K. Arden
Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK
2 shared publications Ali Guermazi
Quantitative Imaging Center, Department of Radiology, Boston University School of Medicine, Boston, MA, USA
1 shared publicationAmanda Dudley
Neuroscience, Innovative Medicines and Early Development, AstraZeneca, Cambridge, United Kingdom
1 shared publicationAndrew Murray
Centre for Sport and Exercise, University of Edinburgh, Edinburgh, UK
1 shared publication
Latest Publications
- Open Access
- 30 June 2025
- Published by The Korean Spinal Neurosurgery Society in Neurospine
- Vol. 22 (2) , 523-539
Rates, Causes, and Predictive Factors of Hospital Readmissions After Spine Surgery for Lumbar Spinal Stenosis: A Nationwide Retrospective Cohort Study
Objective: This study aimed to determine the rates, causes, and predictive factors of readmissions at different periods following spine surgery, up to 180 days.Methods: This study utilized data from the 2018 to 2019 Nationwide Readmissions Database and included four postoperative periods: 0 to 7 days, 8 to 30 days, 31 to 90 days, and 91 to 180 days. The causes of readmissions and potential predictive factors were systematically identified. All analyses were performed for each period.Results: For the 180,281 patients (mean age, 65.4 years) included, 2.4% were readmitted between 0 and 7 days, 3.5% between 8 and 30 days, 3.7% between 31 and 90 days, and 4.3% between 91 and 180 days (cumulative rates: 2.4%, 5.9%, 9.3%, and 12.1%, respectively). The causes of readmissions varied across different periods: surgical site-related causes predominated within the first 30 days, whereas nonsurgical site-related causes were more prevalent from 31 to 180 days; other surgical care complication (e.g., infection) was the most prevalent cause between 0 and 7 days (10.7%) and between 8 and 30 days (29.2%), while spondylopathies/spondyloarthropathy (e.g., spinal stenosis) were the leading causes between 31 and 90 days (12.6%) and between 91 and 180 days (17.5%). The predictive factors associated with readmissions also varied across different periods. For example, patients who underwent fusion was associated with a decreased risk of readmissions between 31 and 180 days (e.g., between 91 and 180 days: odds ratio [OR], 0.79; 95% confidence interval [CI], 0.72–0.86; p<0.001), rather than between 0 and 30 days (e.g., between 0 and 7 days: OR, 0.99; 95% CI, 0.90–1.08; p=0.81).Conclusion: About 6% of patients with lumbar spinal stenosis who underwent spine surgery were readmitted within 30 days and 12% by 180 days. The causes of readmissions and predictive factors varied by period, providing valuable insights for quality improvement efforts and the burden of readmission reductions.
- 30 June 2025
- Published by The Korean Spinal Neurosurgery Society in Neurospine
- Vol. 22 (2) , 523-539
Open AccessRates, Causes, and Predictive Factors of Hospital Readmissions After Spine Surgery for Lumbar Spinal Stenosis: A Nationwide Retrospective Cohort Study
Objective: This study aimed to determine the rates, causes, and predictive factors of readmissions at different periods following spine surgery, up to 180 days.Methods: This study utilized data from the 2018 to 2019 Nationwide Readmissions Database and included four postoperative periods: 0 to 7 days, 8 to 30 days, 31 to 90 days, and 91 to 180 days. The causes of readmissions and potential predictive factors were systematically identified. All analyses were performed for each period.Results: For the 180,281 patients (mean age, 65.4 years) included, 2.4% were readmitted between 0 and 7 days, 3.5% between 8 and 30 days, 3.7% between 31 and 90 days, and 4.3% between 91 and 180 days (cumulative rates: 2.4%, 5.9%, 9.3%, and 12.1%, respectively). The causes of readmissions varied across different periods: surgical site-related causes predominated within the first 30 days, whereas nonsurgical site-related causes were more prevalent from 31 to 180 days; other surgical care complication (e.g., infection) was the most prevalent cause between 0 and 7 days (10.7%) and between 8 and 30 days (29.2%), while spondylopathies/spondyloarthropathy (e.g., spinal stenosis) were the leading causes between 31 and 90 days (12.6%) and between 91 and 180 days (17.5%). The predictive factors associated with readmissions also varied across different periods. For example, patients who underwent fusion was associated with a decreased risk of readmissions between 31 and 180 days (e.g., between 91 and 180 days: odds ratio [OR], 0.79; 95% confidence interval [CI], 0.72–0.86; p<0.001), rather than between 0 and 30 days (e.g., between 0 and 7 days: OR, 0.99; 95% CI, 0.90–1.08; p=0.81).Conclusion: About 6% of patients with lumbar spinal stenosis who underwent spine surgery were readmitted within 30 days and 12% by 180 days. The causes of readmissions and predictive factors varied by period, providing valuable insights for quality improvement efforts and the burden of readmission reductions.
- Open Access
- 11 January 2024
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 54 (8) , 1693-1701
The causal association between maternal depression, anxiety, and infection in pregnancy and neurodevelopmental disorders among 410 461 children: a population study using quasi-negative control cohorts and sibling analysis
Background: To address if the long-standing association between maternal infection, depression/anxiety in pregnancy, and offspring neurodevelopmental disorder (NDD) is causal, we conducted two negative-control studies.Methods: Four primary care cohorts of UK children (pregnancy, 1 and 2 years prior to pregnancy, and siblings) born between 1 January 1990 and 31 December 2017 were constructed. NDD included autism/autism spectrum disorder, attention-deficit/hyperactivity disorder, intellectual disability, cerebral palsy, and epilepsy. Maternal exposures included depression/anxiety and/or infection. Maternal (age, smoking status, comorbidities, body mass index, NDD); child (gender, ethnicity, birth year); and area-level (region and level of deprivation) confounders were captured. The NDD incidence rate among (1) children exposed during or outside of pregnancy and (2) siblings discordant for exposure in pregnancy was compared using Cox-regression models, unadjusted and adjusted for confounders.Results: The analysis included 410 461 children of 297 426 mothers and 2 793 018 person-years of follow-up with 8900 NDD cases (incidence rate = 3.2/1000 person years). After adjustments, depression and anxiety consistently associated with NDD (pregnancy-adjusted HR = 1.58, 95% CI 1.46–1.72; 1-year adj. HR = 1.49, 95% CI 1.39–1.60; 2-year adj. HR = 1.62, 95% CI 1.50–1.74); and to a lesser extent, of infection (pregnancy adj. HR = 1.16, 95% CI 1.10–1.22; 1-year adj. HR = 1.20, 95% CI 1.14–1.27; 2-year adj. HR = 1.19, 95% CI 1.12–1.25). NDD risk did not differ among siblings discordant for pregnancy exposure to mental illness HR = 0.97, 95% CI 0.77–1.21 or infection HR = 0.99, 95% CI 0.90–1.08.Conclusions: Maternal risk appears to be unspecific to pregnancy: our study provided no evidence of a specific, and therefore causal, link between in-utero exposure to infection, common mental illness, and later development of NDD.
- 11 January 2024
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 54 (8) , 1693-1701
Open AccessThe causal association between maternal depression, anxiety, and infection in pregnancy and neurodevelopmental disorders among 410 461 children: a population study using quasi-negative control cohorts and sibling analysis
Background: To address if the long-standing association between maternal infection, depression/anxiety in pregnancy, and offspring neurodevelopmental disorder (NDD) is causal, we conducted two negative-control studies.Methods: Four primary care cohorts of UK children (pregnancy, 1 and 2 years prior to pregnancy, and siblings) born between 1 January 1990 and 31 December 2017 were constructed. NDD included autism/autism spectrum disorder, attention-deficit/hyperactivity disorder, intellectual disability, cerebral palsy, and epilepsy. Maternal exposures included depression/anxiety and/or infection. Maternal (age, smoking status, comorbidities, body mass index, NDD); child (gender, ethnicity, birth year); and area-level (region and level of deprivation) confounders were captured. The NDD incidence rate among (1) children exposed during or outside of pregnancy and (2) siblings discordant for exposure in pregnancy was compared using Cox-regression models, unadjusted and adjusted for confounders.Results: The analysis included 410 461 children of 297 426 mothers and 2 793 018 person-years of follow-up with 8900 NDD cases (incidence rate = 3.2/1000 person years). After adjustments, depression and anxiety consistently associated with NDD (pregnancy-adjusted HR = 1.58, 95% CI 1.46–1.72; 1-year adj. HR = 1.49, 95% CI 1.39–1.60; 2-year adj. HR = 1.62, 95% CI 1.50–1.74); and to a lesser extent, of infection (pregnancy adj. HR = 1.16, 95% CI 1.10–1.22; 1-year adj. HR = 1.20, 95% CI 1.14–1.27; 2-year adj. HR = 1.19, 95% CI 1.12–1.25). NDD risk did not differ among siblings discordant for pregnancy exposure to mental illness HR = 0.97, 95% CI 0.77–1.21 or infection HR = 0.99, 95% CI 0.90–1.08.Conclusions: Maternal risk appears to be unspecific to pregnancy: our study provided no evidence of a specific, and therefore causal, link between in-utero exposure to infection, common mental illness, and later development of NDD.
- 1 February 2022
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 52, 151935
Effects of body weight and fat mass on back pain – direct mechanical or indirect through inflammatory and metabolic parameters?
- 1 February 2022
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 52, 151935
Effects of body weight and fat mass on back pain – direct mechanical or indirect through inflammatory and metabolic parameters?
- Open Access
- 1 January 2022
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 141, 54-63
Specific body mass index trajectories were related to musculoskeletal pain and mortality: 19‐year follow‐up cohort
- 1 January 2022
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 141, 54-63
Open AccessSpecific body mass index trajectories were related to musculoskeletal pain and mortality: 19‐year follow‐up cohort
- Open Access
Rugby Health and Well-Being Study: protocol for a UK-wide survey with health data cross-validation
Introduction Rugby football (Union and League) provides physical activity (PA) with related physical and mental health benefits. However, as a collision sport, rugby research and media coverage predominantly focus on injuries in elite players while the overall impact on health and well-being remains unclear. This study aims to provide a greater understanding of the risks and benefits of rugby participation in a diverse sample of men and women, current and former rugby Union and League players from recreational to the elite level of play. We will explore: (1) joint-specific injuries and concussion; (2) joint pain and osteoarthritis (OA); (3) medical and mental health conditions; (4) PA and sedentary behaviour and (5) well-being (quality of life, flourishing and resilience). Methods and analysis The Rugby Health and Well-being Study is designed in two phases: (1) a UK-wide cross-sectional survey and (2) cross-validation using health register data from Scotland. Participants will be at least 16 years old, current or former rugby players who have played rugby for at least one season. We will report standardised, level of play-, sex- and age-stratified prevalence of joint injury, concussion, medical conditions and PA. We will describe injury/concussion prevention expectations and protective equipment use. Rugby-related factors associated with injury, pain, OA, PA, health and well-being will be explored in regression models. We will compare joint pain intensity and duration, elements of pain perception and well-being between recreational and elite players and further investigate these associations in regression models while controlling for confounding variables. In the second phase, we will validate self-reported with health register data, and provide further information on healthcare use. Ethics and dissemination The Yorkshire and the Humber—Leeds East Research Ethics Committee (REC reference: 19/HY/0377) has approved this study (IRAS project ID 269424). The results will be disseminated through scientific publications, conferences and social media.
Open AccessRugby Health and Well-Being Study: protocol for a UK-wide survey with health data cross-validation
Introduction Rugby football (Union and League) provides physical activity (PA) with related physical and mental health benefits. However, as a collision sport, rugby research and media coverage predominantly focus on injuries in elite players while the overall impact on health and well-being remains unclear. This study aims to provide a greater understanding of the risks and benefits of rugby participation in a diverse sample of men and women, current and former rugby Union and League players from recreational to the elite level of play. We will explore: (1) joint-specific injuries and concussion; (2) joint pain and osteoarthritis (OA); (3) medical and mental health conditions; (4) PA and sedentary behaviour and (5) well-being (quality of life, flourishing and resilience). Methods and analysis The Rugby Health and Well-being Study is designed in two phases: (1) a UK-wide cross-sectional survey and (2) cross-validation using health register data from Scotland. Participants will be at least 16 years old, current or former rugby players who have played rugby for at least one season. We will report standardised, level of play-, sex- and age-stratified prevalence of joint injury, concussion, medical conditions and PA. We will describe injury/concussion prevention expectations and protective equipment use. Rugby-related factors associated with injury, pain, OA, PA, health and well-being will be explored in regression models. We will compare joint pain intensity and duration, elements of pain perception and well-being between recreational and elite players and further investigate these associations in regression models while controlling for confounding variables. In the second phase, we will validate self-reported with health register data, and provide further information on healthcare use. Ethics and dissemination The Yorkshire and the Humber—Leeds East Research Ethics Committee (REC reference: 19/HY/0377) has approved this study (IRAS project ID 269424). The results will be disseminated through scientific publications, conferences and social media.
- Open Access
- 24 June 2020
- Published by Wolters Kluwer Health in Pain
- Vol. 161 (12) , 2841-2851
Pain trajectory defines knee osteoarthritis subgroups: a prospective observational study
Knee osteoarthritis (OA) is a heterogeneous disease, and identification of its subgroups/phenotypes can improve patient treatment and drug development. We aimed to identify homogeneous OA subgroups/phenotypes using pain development over time; to understand the interplay between pain and functional limitation in time course; and to investigate subgroups' responses to available pharmacological and surgical treatments. We used group-based trajectory modelling to identify pain trajectories in the phase-3 VIDEO trial (n = 474, 3-year follow-up) and also in the Osteoarthritis Initiative cohort study (n = 4796, 9-year follow-up). We extended trajectory models by (1) fitting dual trajectories to investigate the interplay between pain and functional limitation over time, and (2) including analgesic use as a time-varying covariate. Also, we investigated the relationship between trajectory groups and knee replacement in regression models. We identified 4 pain trajectory groups in the trial and 6 in the cohort. These overlapped and led us to define 4 OA phenotypes: low-fluctuating, mild-increasing, moderate-treatment-sensitive, and severe-treatment-insensitive pain. Over time, functional knee limitation followed the same trajectory as pain with almost complete concordance (94.3%) between pain and functional limitation trajectory groups. Notably, we identified a phenotype with severe pain that did not benefit from available treatments, and another one most likely to benefit from knee replacement. Thus, knee OA subgroups/phenotypes can be identified based on patients' pain experiences in studies with long and regular follow-up. We provided a robust approach, reproducible between different study designs, which informs clinicians about symptom development and delivery of treatment options and opens a new avenue toward personalized medicine in OA.
- 24 June 2020
- Published by Wolters Kluwer Health in Pain
- Vol. 161 (12) , 2841-2851
Open AccessPain trajectory defines knee osteoarthritis subgroups: a prospective observational study
Knee osteoarthritis (OA) is a heterogeneous disease, and identification of its subgroups/phenotypes can improve patient treatment and drug development. We aimed to identify homogeneous OA subgroups/phenotypes using pain development over time; to understand the interplay between pain and functional limitation in time course; and to investigate subgroups' responses to available pharmacological and surgical treatments. We used group-based trajectory modelling to identify pain trajectories in the phase-3 VIDEO trial (n = 474, 3-year follow-up) and also in the Osteoarthritis Initiative cohort study (n = 4796, 9-year follow-up). We extended trajectory models by (1) fitting dual trajectories to investigate the interplay between pain and functional limitation over time, and (2) including analgesic use as a time-varying covariate. Also, we investigated the relationship between trajectory groups and knee replacement in regression models. We identified 4 pain trajectory groups in the trial and 6 in the cohort. These overlapped and led us to define 4 OA phenotypes: low-fluctuating, mild-increasing, moderate-treatment-sensitive, and severe-treatment-insensitive pain. Over time, functional knee limitation followed the same trajectory as pain with almost complete concordance (94.3%) between pain and functional limitation trajectory groups. Notably, we identified a phenotype with severe pain that did not benefit from available treatments, and another one most likely to benefit from knee replacement. Thus, knee OA subgroups/phenotypes can be identified based on patients' pain experiences in studies with long and regular follow-up. We provided a robust approach, reproducible between different study designs, which informs clinicians about symptom development and delivery of treatment options and opens a new avenue toward personalized medicine in OA.
- 22 March 2017
- Published by Wolters Kluwer Health in Pain
- Vol. 158 (7) , 1254-1263
Biomarker of extracellular matrix remodelling C1M and proinflammatory cytokine interleukin 6 are related to synovitis and pain in end-stage knee osteoarthritis patients
Little is known about local and systemic biomarkers in relation to synovitis and pain in end-stage osteoarthritis (OA) patients. We investigated the associations between the novel extracellular matrix biomarker, C1M, and local and systemic interleukin 6 (IL-6) with synovitis and pain. Serum C1M, plasma, and synovial fluid IL-6 (p-IL-6, sf-IL-6) were measured in 104 end-stage knee OA patients. Contrast-enhanced magnetic resonance imaging was used to semiquantitatively assess an 11-point synovitis score; pain was assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and the Neuropathic Pain Questionnaire (NPQ). Linear regression was used to investigate associations between biomarkers and synovitis, and biomarkers and pain while controlling for age, sex, and body mass index. We also tested whether associations between biomarkers and pain were confounded by synovitis. We found sf-IL-6 was associated with synovitis in the parapatellar subregion (B = 0.006; 95% confidence interval [CI] 0.003-0.010), and no association between p-IL-6 and synovitis. We also observed an association between C1M and synovitis in the periligamentous subregion (B = 0.013; 95% CI 0.003-0.023). Furthermore, sf-IL-6, but not p-IL-6, was significantly associated with pain, WOMAC (B = 0.022; 95% CI 0.004-0.040), and NPQ (B = 0.043; 95% CI 0.005-0.082). There was no association between C1M and WOMAC pain, but we did find an association between C1M and NPQ (B = 0.229; 95% CI 0.036-0.422). Lastly, synovitis explained both biomarker-NPQ associations, but not the biomarker-WOMAC association. These results suggest that C1M and IL-6 are associated with synovitis and pain, and synovitis is an important confounding variable when studying biomarkers and neuropathic features in OA patients.
- 22 March 2017
- Published by Wolters Kluwer Health in Pain
- Vol. 158 (7) , 1254-1263
Biomarker of extracellular matrix remodelling C1M and proinflammatory cytokine interleukin 6 are related to synovitis and pain in end-stage knee osteoarthritis patients
Little is known about local and systemic biomarkers in relation to synovitis and pain in end-stage osteoarthritis (OA) patients. We investigated the associations between the novel extracellular matrix biomarker, C1M, and local and systemic interleukin 6 (IL-6) with synovitis and pain. Serum C1M, plasma, and synovial fluid IL-6 (p-IL-6, sf-IL-6) were measured in 104 end-stage knee OA patients. Contrast-enhanced magnetic resonance imaging was used to semiquantitatively assess an 11-point synovitis score; pain was assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and the Neuropathic Pain Questionnaire (NPQ). Linear regression was used to investigate associations between biomarkers and synovitis, and biomarkers and pain while controlling for age, sex, and body mass index. We also tested whether associations between biomarkers and pain were confounded by synovitis. We found sf-IL-6 was associated with synovitis in the parapatellar subregion (B = 0.006; 95% confidence interval [CI] 0.003-0.010), and no association between p-IL-6 and synovitis. We also observed an association between C1M and synovitis in the periligamentous subregion (B = 0.013; 95% CI 0.003-0.023). Furthermore, sf-IL-6, but not p-IL-6, was significantly associated with pain, WOMAC (B = 0.022; 95% CI 0.004-0.040), and NPQ (B = 0.043; 95% CI 0.005-0.082). There was no association between C1M and WOMAC pain, but we did find an association between C1M and NPQ (B = 0.229; 95% CI 0.036-0.422). Lastly, synovitis explained both biomarker-NPQ associations, but not the biomarker-WOMAC association. These results suggest that C1M and IL-6 are associated with synovitis and pain, and synovitis is an important confounding variable when studying biomarkers and neuropathic features in OA patients.